Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01129557
Other study ID # AAAE0863
Secondary ID #IIRP-906
Status Terminated
Phase Phase 4
First received May 21, 2010
Last updated April 16, 2014
Start date September 2009
Est. completion date December 2012

Study information

Verified date April 2014
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months). The investigators hypothesize that aldosterone breakthrough occurs due to accumulation of active precursor substances, most notably angiotensin II, produced in response to conventional RAAS blockade with ACEinhibitors and ARBs. The investigators believe that direct renin inhibition (DRI) should minimize this accumulation and therefore significantly lower or possibly eliminate the breakthrough effect.

Interruption of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), alone and in combination, has become a leading therapy to slow the progression of chronic heart and kidney disease. Both types of drugs inhibit the formation of aldosterone, a hormone, which has been shown to have harmful effects on patients with chronic heart and kidney disorders. This treatment is effective but not perfect since, even after an initial improvement, many patients become worse over the long term. This may be due to an unexpected increase in aldosterone, a phenomenon called "aldosterone breakthrough."

The purpose of this study is to find out whether the use of a direct renin inhibitor (DRI) alone, or in combination with an angiotensin receptor blocker (ARB), will lessen the occurrence of aldosterone breakthrough since direct renin inhibitors inhibit the formation of aldosterone at a very early step. This study will compare the effectiveness of adding Diovan (valsartan) or Tekturna (aliskiren) or a combination of Diovan and Tekturna to the usual antihypertensive treatment. The investigators will follow blood pressure, aldosterone levels, and urinary protein levels over 9 months to evaluate which of these therapies is most effective for treating hypertension in patients with proteinuric kidney disease.


Description:

This is a randomized, open-label, three-arm study comparing Diovan (valsartan, an ARB), Tekturna (aliskiren, a DRI), and the combination of valsartan + aliskiren (i.e. ARB + DRI). One hundred twenty subjects (40 per arm) will be treated with Tekturna, Diovan, or a combination of both drugs for 9 months on top of their usual antihypertensive treatment. Changes in urinary aldosterone excretion will be monitored during therapy to measure the incidence of aldosterone breakthrough, defined as any sustained positive change from baseline urinary aldosterone excretion by the completion of the 9-month study period. This frequency measure will be compared during ARB, DRI, and ARB + DRI therapy. Changes in urinary protein excretion will also be monitored alongside the urinary aldosterone levels to determine whether aldosterone breakthrough is associated with refractory proteinuria. This is an innovative study that will be the first to (1) examine aldosterone breakthrough during DRI therapy, and (2) explore whether addition of a DRI to an ARB protects against aldosterone breakthrough. In addition, this will be the first study to examine whether DRI therapy (alone or in combination with ARB) is effective therapy for hypertension in patients with non-diabetic proteinuric kidney disease.


Recruitment information / eligibility

Status Terminated
Enrollment 46
Est. completion date December 2012
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Proteinuria > 300 mg/day

- Normal to mildly reduced kidney function (eGFR > 45 ml/min/1.73m2)

- Systolic blood pressure >130 mm Hg

- Diastolic blood pressure >70 mm Hg

- Diagnoses of diabetic nephropathy, hypertensive nephrosclerosis, IgA nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, membranous nephropathy, fibrillary glomerulonephritis, or obesity-associated glomerulopathy

Exclusion Criteria:

- Concomitant use of cyclosporine (which can interact with aliskiren)

- Inability to undergo 6 week washout period if already on RAAS-blocking drug(s) (includes renin inhibitor, ACE-inhibitor, ARB, and mineralocorticoid receptor blocker)

- eGFR < 45 ml/min/1.73m2

- Urine protein excretion < 300 mg/day

- Serum K > 5.0 mEq/l

- Systolic blood pressure > 170 mm Hg or < 130 mm Hg after washout period

- Diastolic blood pressure > 110 mm Hg or < 70 mm Hg after washout period

- Congestive heart failure NYHA class III and IV

- History of any cardiovascular events (stroke, TIA, MI, unstable angina, CABG, PCI, CHF hospitalization) in 3 months prior to study visit 1

- 2nd or 3rd degree heart block without a pacemaker or other uncontrolled arrhythmia

- Clinically significant valvular disease

- Known renal artery stenosis

- Any surgical or medical condition that might significantly alter the pharmacokinetics of the study drugs (n.b. bariatric surgery > 6 months prior to visit 1 is not an exclusion)

- History or evidence of drug or alcohol abuse within the last 12 months

- Any concurrent life threatening condition with a life expectancy less than 2 years

- Pregnant or nursing (lactating) women

- Women of child-bearing potential unless postmenopausal for at least 1 year, surgically sterile, or using effective methods of contraception as defined by local health authorities

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Aliskiren

Valsartan


Locations

Country Name City State
United States Columbia University Medical Center New York New York

Sponsors (2)

Lead Sponsor Collaborator
Columbia University Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertens. 2012 Sep-Oct;6(5):338-45. doi: 10.1016/j.jash.2012.07.003 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol. The primary outcome of this study is the 9-month cumulative incidence of aldosterone breakthrough, defined as a sustained increase in 24-hour urine aldosterone above baseline, in each treatment arm. 9 months No
Secondary Serum Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough. Mean serum aldosterone at baseline, 3-, 6-, and 9-months. Baseline, 3-, 6-, and 9-months No
Secondary Urine Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough. Mean urine aldosterone at baseline, 3-, 6-, and 9-months. Baseline, 3-, 6-, and 9-months No
Secondary Serum Potassium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough. Mean serum potassium at baseline, 3-, 6-, and 9-months. (given as reference to interpret contemporaneous plasma & urine aldosterone measurements.) Baseline, 3-, 6-, and 9-months No
Secondary Mean 24-hour Urine Sodium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough. Mean 24-hour urine sodium (mmol/day) at baseline, 3-, 6-, and 9-months. (given as reference to interpret contemporaneous plasma & urine aldosterone measurements.) Baseline, 3-, 6-, and 9-months No
Secondary Pre- and Post-treatment Blood Pressure in Subjects With and Without Aldosterone Breakthrough. Compares baseline and final (9 month) blood pressure for subjects with and without aldosterone breakthrough Baseline and Final (9 month) No
Secondary Pre- and Post-treatment Serum Creatinine in Subjects With and Without Aldosterone Breakthrough. Compares baseline and final (9 month) serum creatinine for subjects with and without aldosterone breakthrough Baseline and Final (9 month) No
Secondary Pre- and Post-treatment Serum Potassium in Subjects With and Without Aldosterone Breakthrough. Compares baseline and final (9 month) serum potassium for subjects with and without aldosterone breakthrough Baseline and Final (9 month) No
Secondary Pre- and Post-treatment 24-hour Urine Protein in Subjects With and Without Aldosterone Breakthrough. Compares baseline and final (9 month) 24-hour urine protein for subjects with and without aldosterone breakthrough Baseline and Final (9 month) No
Secondary Pre- and Post-treatment 24-hour Urine Sodium in Subjects With and Without Aldosterone Breakthrough. Compares baseline and final (9 month) 24-hour urine sodium for subjects with and without aldosterone breakthrough Baseline and Final (9 month) No
Secondary Pre- and Post-treatment 24-urine Aldosterone in Subjects With and Without Aldosterone Breakthrough. Compares baseline and final (9 month) 24-hour urine aldosterone for subjects with and without aldosterone breakthrough Baseline and Final (9 month) No
Secondary Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough. Compares baseline and final (9 month) serum aldosterone for subjects with and without aldosterone breakthrough Baseline and Final (9 month) No
See also
  Status Clinical Trial Phase
Recruiting NCT04562025 - Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy N/A
Not yet recruiting NCT03658317 - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy N/A
Recruiting NCT02501772 - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy N/A
Completed NCT02829177 - Microalbuminuria and Allopurinol in Type 1 Diabetes Phase 4
Completed NCT02251067 - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients Phase 2
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Completed NCT01440257 - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria Phase 2
Active, not recruiting NCT01273675 - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy N/A
Completed NCT00317954 - Spironolactone in Diabetic Nephropathy Phase 4
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Not yet recruiting NCT05061459 - The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
Completed NCT01935167 - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01673204 - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Phase 4
Completed NCT01726816 - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01458158 - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease N/A
Completed NCT01447147 - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy Phase 2
Completed NCT01476501 - Vitamin D Supplementation in Diabetic Nephropathy Phase 2
Completed NCT01003236 - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy Phase 2
Completed NCT00535925 - Nephropathy In Type 2 Diabetes and Cardio-renal Events Phase 4
Completed NCT00097955 - Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria Phase 2